Bausch Health Options Traders: Stock Will Remain Below This Level Through July Expiration
Portfolio Pulse from Priya Nigam
Bausch Health Companies Inc. (NYSE:BHC) shares rose sharply after the U.S. District Court of Delaware upheld the final judgment for XIFAXAN 550 mg, preventing FDA approval of Norwich's abbreviated new drug application until 2029. A trader expects Bausch Health's stock to remain below $9 through July expiration.
May 18, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch Health's stock rose after a court ruling upheld the final judgment for XIFAXAN 550 mg, preventing FDA approval of Norwich's drug application until 2029. A trader expects the stock to remain below $9 through July expiration.
The court ruling prevents FDA approval of a competing drug, which is positive for Bausch Health. The trader's expectation of the stock remaining below $9 through July suggests a cautious outlook, but the stock has already risen sharply, indicating a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100